New research suggests that individuals who discontinue popular GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight far faster than those who end traditional lifestyle plans.
Research printed in a prominent medical journal points out that while obese people frequently drop about a fifth of their body weight while undergoing treatment, the weight returns at an average rate of nearly a kilo each month after stopping.
"Users using such treatments need to be cognizant of the danger of fast weight regain when the treatment concludes," warns lead investigator Dr. Susan Jebb.
This pace of recovery suggests a reversion to starting weight in about one and a half years.
Comparing Therapies
The study, which examined dozens of trials involving thousands of participants, compared the outcomes of these new drugs with older methods.
Researchers note that people who lose weight through dieting usually see a less rapid creep back—approximately 100 grams monthly—once they finish.
Understanding the Quick Regain
Doctors believe the mode of action of the drugs explains the accelerated weight return.
GLP-1 drugs copy a natural hormone called GLP-1, which helps regulate appetite.
"Long-term administration of the hormone concentrations several times higher than normal might result in the system to produce less of its own natural hormone, and may also reduce sensitivity to its effects," said Dr. Adam Collins, a nutrition expert.
"Withdrawal of this GLP-1 'fix' leads to hunger is unsuppressed, making binge eating much more probable."
An Ongoing Disease?
Health authorities advise the injections for individuals with obesity-related medical conditions, alongside recommended lifestyle changes.
Many experts contend that, given the high risk of relapse, the therapy should be considered life-long.
This opinion is supported by pharmaceutical companies, who say that the results "highlight the chronic nature of excess weight," similar to managing conditions like hypertension.
User Experiences
People who have come off the jabs describe a powerful resurgence of appetite.
"It was like a switch flipping and you're instantly starving," said one woman.
This difficulty is compounded if individuals have not developed permanent lifestyle or habit changes during treatment.
Growing Adoption
Recent estimates suggest that a significant number of adults in the UK have tried weight-loss jabs in the past year, with interest remaining high.
- Adoption is more common among females than men.
- The 40s and 50s demographic shows the greatest usage rates.
- Many access the medications through private healthcare rather than the NHS.
Ultimately, clinicians caution that while GLP-1 drugs are powerful tools for shedding pounds, they are not a permanent cure and maintained weight loss relies on integrated lifestyle management.
